Frank SC, et al. - Researchers examined the new point-of-care (POC) assays for early infant HIV diagnosis for their clinical benefits. In addition, they determined cost-effectiveness of incorporating these POC assays into early infant diagnosis programmes in Zimbabwe using the Cost Effectiveness of Preventing AIDS Complications (CEPAC)—Pediatric model. Using conventional assays for early infant diagnosis, they observed projected undiscounted life expectancy of 22·7 years for infants with HIV and 62·5 years for all HIV-exposed infants, at a cost of $610 per HIV-exposed infant. Using POC assays for early infant HIV diagnosis, they observed improvement in projected undiscounted life expectancy to 25·5 years among infants with HIV and 62·6 years among HIV-exposed infants at a cost of $690 per HIV-exposed infant. Outcomes thus suggest that POC assays for early infant HIV diagnosis in Zimbabwe may improve survival, extend life expectancy, and be cost-effective for HIV-exposed infants when compared with conventional assays.